Researchers developed a highly accurate model that can predict which patients will achieve complete response to chimeric antigen receptor T-cell therapy for multiple myeloma.
The model is based on clinical and metabolic data plus gut microbiome composition genomic analysis, according to findings presented at European Society for Blood and Marrow Transplantation-European Hematology Association 5th European CAR T-cell Meeting.
Previous study results suggested the gastrointestinal microbiome can impact T-cell phenotype and function, in addition to modulating the body’s antitumor immune response,
